Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.60 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742457 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL14134478 | 0.86 | SMN1; SMN2 (0.65) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL3933899 | 0.86 | SMN1; SMN2 (0.65) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4865927 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4968797 | 0.83 | SMN1; SMN2 (0.65) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL3933173 | 0.81 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL2612387 | 0.81 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL1742461 | 0.81 | PTPRB (0.49) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4890267 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4068199 | 0.80 | SMN1; SMN2 (0.71) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| CN-101421265-A | Thiazole compounds as protein kinase b (pkb) inhibitors | AMGEN INC (US) | 2009-04-29 | — | — | CN | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | SMN1; SMN2 2808/4885KMT2A 3711/4885NPC1 637/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | SMN1; SMN2 3662/4885KMT2A 3968/4885NPC1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.